GLP-1 Agonists and Muscle Mass: How Much Lean Tissue Is Lost?

Body composition data from STEP-1 and SURMOUNT-1

The STEP-1 body-composition substudy enrolled 140 participants who underwent DEXA at baseline and week 68. Total fat mass decreased by 8.4 kg in the semaglutide group versus 1.5 kg in placebo, while lean body mass decreased by 5.3 kg versus 1.6 kg¹. Fat-free mass accounted for roughly 39% of total weight loss.

The SURMOUNT-1 DEXA substudy of 160 participants showed similar findings: approximately 33.9% reduction in total fat mass and 10.9% reduction in lean mass at the 15 mg tirzepatide dose at 72 weeks². Across both trials, the ratio of fat-to-lean-mass loss is consistent with what dietary weight loss produces — the caloric deficit, not the GLP-1 mechanism itself, drives lean-mass loss.

Why lean mass matters in older adults

Sarcopenia is a recognized risk factor for falls, fractures, hospitalization, and all-cause mortality³. Adults over 65 lose 0.5-1.0% of lean mass per year through normal aging. Rapid pharmacologic weight loss can compress years of lean-mass loss into months. A patient aged 70 with 90 kg starting weight who loses 18 kg on tirzepatide (20%) may lose 5-6 kg of lean mass — clinically meaningful for grip strength, gait speed, and functional independence.

Protein and resistance training mitigation

ESPEN recommends 1.2-1.5 g/kg/day protein for older adults and 1.2-1.6 g/kg adjusted body weight/day during weight loss&sup4;. This is 50-100% higher than the standard 0.8 g/kg/day RDA.

Resistance training during caloric restriction reduces lean-mass loss by approximately 50% in meta-analyses of older adults&sup5;. The recommendation that emerges consistently: protein-prioritized eating + resistance training, started early, preserves function. Patients on GLP-1 therapy who are sedentary and undereating protein represent the highest-risk phenotype for clinically significant sarcopenia.

Clinical monitoring

Routine DEXA is not standard. Clinically actionable surrogates include grip strength (handgrip dynamometer), gait speed (4-meter walk), and the Short Physical Performance Battery. EWGSOP2 defines probable sarcopenia by low grip strength alone (<27 kg men, <16 kg women)³. Patients on GLP-1 with declining grip strength, new falls, or new functional complaints warrant nutritional review and consideration of dose reduction or transition to maintenance dosing.

Related editorial coverage

• STEP-1 trial — full results
• SURMOUNT-1 trial
• GLP-1 agonists in older adults

Frequently asked questions

Do GLP-1 drugs cause more muscle loss than diet alone?

Not appreciably. The ratio of fat-to-lean-mass loss is similar to caloric restriction alone. Absolute amounts are higher because total weight loss is higher, but proportionally similar.

How much protein should I eat on semaglutide or tirzepatide?

1.2 to 1.6 g/kg adjusted body weight/day during active weight loss, with the upper end favored for older adults. For a 90 kg patient, that is roughly 100-130 g/day distributed across 3-4 meals.

Will I get my muscle back after stopping?

Lean mass returns more slowly than fat mass after weight loss ends. Resistance training during and after weight loss substantially improves recovery.

Is sarcopenia a contraindication to GLP-1 therapy?

Not a labeled contraindication. Pre-existing sarcopenia is a relative concern; weight loss should be slower, protein and resistance training prescribed proactively, and goal weight individualized to function rather than BMI alone.

Does tirzepatide cause more muscle loss than semaglutide?

Per-percent-weight-loss ratios are similar across both molecules. Absolute lean-mass loss can be higher on tirzepatide because total weight loss is higher.